Taiwan · Delayed Price · Currency is TWD Energenesis Biomedical CO.,LTD. Company Description
Energenesis Biomedical CO.,LTD. operates in the biomedicine industry in Taiwan. It provides ENERGI-F703, which is Phase II clinical trial for use in treatment of diabetic foot ulcers; ENERGI-F701, a topical tonic for the treatment of alopecia that is in Phase II clinical trial; ENERGI-F711, a burn cream; ENERGI-F702 to treat metabolic diseases; ENERGI-F704 for the treatment of inflammatory bowel disease; ENERGI-F708 for asthma treatment; ENERGI-F705 for Parkinson's disease control; ENERGI-F707 for the treatment of mitochondria deficiency; ENERGI-F706 to treat cachexia; ENERGI-F709, a vaccine adjuvant; and ENERGI-F710 for blood phosphate control.
The company also offers scientific products, which include western blot, cell culture supplement, protein isolation, protein quantification, dyes, and buffer solutions.
Energenesis Biomedical CO.,LTD. was founded in 2012 and is based in Taipei, Taiwan.
| Country | Taiwan |
| Founded | 2012 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 35 |
| CEO | Han-min Chen |
Contact Details
Address: No.21, Ln.583, Ruiguang Road Taipei, 11492 Taiwan | |
| Phone | 886 2 2627 0835 |
| Website | energenesis-biomedical.com |
Stock Details
| Ticker Symbol | 6657 |
| Exchange | Taiwan Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | TWD |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Han-min Chen | Co-Founder, Chairman and GM |
| Jen-yi Chiu | Co-Founder |
| Pei-chao Chen | Director of Accounting |
| Ming-tsan Chiang | Vice President, Corporate Governance Officer and Director of the General Administrative Division |
| Chueh-Hua Kuo | Chief Internal Auditor |